{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:00:17Z","timestamp":1789884017156,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2003,1]]},"DOI":"10.1067\/mjd.2003.10","type":"journal-article","created":{"date-parts":[[2003,1,9]],"date-time":"2003-01-09T20:26:11Z","timestamp":1042143971000},"page":"68-75","source":"Crossref","is-referenced-by-count":132,"title":["Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-\u03b1 monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris"],"prefix":"10.1067","volume":"48","author":[{"given":"Alice B.","family":"Gottlieb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rallapalli","family":"Ramamurthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsan","family":"Abdulghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pat","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa T.","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adedigbo A.","family":"Fasanmade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1067\/mjd.2003.10_bib1","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1067\/mjd.2003.10_bib2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1084\/jem.164.4.1013","article-title":"Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques","volume":"164","author":"Gottlieb","year":"1986","journal-title":"J Exp Med"},{"key":"10.1067\/mjd.2003.10_bib3","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nm0595-442","article-title":"Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis","volume":"1","author":"Gottlieb","year":"1995","journal-title":"Nat Med"},{"key":"10.1067\/mjd.2003.10_bib4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","volume":"113","author":"Austin","year":"1999","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mjd.2003.10_bib5","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1073\/pnas.86.16.6367","article-title":"Interleukin-6 (IL-6) is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes","volume":"86","author":"Grossman","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1067\/mjd.2003.10_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/1523-1747.ep12514689","article-title":"Localization of neutrophil-activating peptide-1\/interleukin-8-immunoreactivity in normal and psoriatic skin","volume":"96","author":"Sticherling","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mjd.2003.10_bib7","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/BF00455323","article-title":"In situ localization of interferons in psoriatic lesions","volume":"281","author":"Livden","year":"1989","journal-title":"Arch Dermatol Res"},{"key":"10.1067\/mjd.2003.10_bib8","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1084\/jem.168.3.941","article-title":"Detection of a gamma-interferon-induced protein (IP-10) in psoriatic plaques","volume":"168","author":"Gottlieb","year":"1988","journal-title":"J Exp Med"},{"key":"10.1067\/mjd.2003.10_bib9","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","article-title":"Nuclear factor-kappaB-A pivotal transcription factor in chronic inflammatory diseases","volume":"336","author":"Barnes","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1067\/mjd.2003.10_bib10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/archderm.1991.01680050071006","article-title":"Interleukin 1alpha, tumor necrosis factor alpha and interferon gamma in psoriasis","volume":"127","author":"Gomi","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2003.10_bib11","first-page":"129","article-title":"Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis","volume":"138","author":"Nickoloff","year":"1991","journal-title":"Am J Pathol"},{"issue":"Suppl","key":"10.1067\/mjd.2003.10_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/1523-1747.ep12874977","article-title":"Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets","volume":"95","author":"Norris","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mjd.2003.10_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1087-0024.2000.00001.x","article-title":"Structure, function, and molecular control of the skin lymphatic system","volume":"5","author":"Skobe","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mjd.2003.10_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/mc.2940010105","article-title":"TGF-alpha stimulates growth of skin papillomas by autocrine and paracrine mechanisms but does not cause neoplastic progression","volume":"1","author":"Finzi","year":"1988","journal-title":"Mol Carcinog"},{"key":"10.1067\/mjd.2003.10_bib15","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.168.4.1395","article-title":"Keratinocyte growth regulation by the products of immune cells","volume":"168","author":"Hancock","year":"1988","journal-title":"J Exp Med"},{"key":"10.1067\/mjd.2003.10_bib16","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/archderm.1991.01680050115015","article-title":"The cytokine network in psoriasis","volume":"127","author":"Nickoloff","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2003.10_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti-TNF-alpha monoclonal anti-body cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions","volume":"7","author":"Scallon","year":"1995","journal-title":"Cytokine"},{"key":"10.1067\/mjd.2003.10_bib18","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor-alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1067\/mjd.2003.10_bib19","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor-alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1067\/mjd.2003.10_bib20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-alpha for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1067\/mjd.2003.10_bib21","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1067\/mjd.2003.10_bib22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis oral therapy with a new retinoid","volume":"157","author":"Frederiksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1067\/mjd.2003.10_bib23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/1523-1747.ep12471216","article-title":"Changes in keratinocyte maturation during wound healing","volume":"89","author":"Mansbridge","year":"1987","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mjd.2003.10_bib24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/1523-1747.ep12499782","article-title":"Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation","volume":"98","author":"Gottlieb","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mjd.2003.10_bib25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJM199101313240501","article-title":"Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial","volume":"324","author":"Ellis","year":"1991","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1067\/mjd.2003.10_bib26","first-page":"2022","article-title":"Effect of tumor necrosis factor-alpha blockade on synovial histology in spondylo-arthropathy","volume":"43","author":"Baeten","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1067\/mjd.2003.10_bib27","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/art.1780390702","article-title":"Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor-alpha monoclonal antibody treatment in patients with rheumatoid arthritis","volume":"39","author":"Tak","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1067\/mjd.2003.10_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0016-5085(99)70224-6","article-title":"Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis","volume":"116","author":"Baert","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1067\/mjd.2003.10_bib29","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1016\/S0016-5085(00)84404-2","article-title":"Increased peripheral production of TNF-alpha and mucosal levels of activated NFkappaB predict relapse after treatment with infliximab in patients with Crohn's disease","volume":"118","author":"Nikolaus","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1067\/mjd.2003.10_bib30","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0016-5085(00)83475-7","article-title":"Decreased mucosal lymphocyte proliferation following treatment with infliximab in Crohn's disease","volume":"118","author":"Geboes","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1067\/mjd.2003.10_bib31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1034\/j.1600-0625.2002.110201.x","article-title":"Cytokine therapy in dermatology","volume":"11","author":"Asadullah","year":"2002","journal-title":"Exp Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962203500135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962203500135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T13:26:12Z","timestamp":1553952372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962203500135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["S0190962203500135"],"URL":"https:\/\/doi.org\/10.1067\/mjd.2003.10","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}